Advertisement
Australia markets close in 5 hours 3 minutes
  • ALL ORDS

    7,892.90
    -24.20 (-0.31%)
     
  • ASX 200

    7,637.00
    -23.40 (-0.31%)
     
  • AUD/USD

    0.6495
    -0.0002 (-0.03%)
     
  • OIL

    78.14
    -0.40 (-0.51%)
     
  • GOLD

    2,043.00
    +0.30 (+0.01%)
     
  • Bitcoin AUD

    95,936.45
    +8,051.19 (+9.16%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.5990
    +0.0002 (+0.03%)
     
  • AUD/NZD

    1.0654
    +0.0007 (+0.07%)
     
  • NZX 50

    11,690.88
    -72.44 (-0.62%)
     
  • NASDAQ

    17,874.50
    -96.54 (-0.54%)
     
  • FTSE

    7,624.98
    -58.04 (-0.76%)
     
  • Dow Jones

    38,949.02
    -23.39 (-0.06%)
     
  • DAX

    17,601.22
    +44.73 (+0.25%)
     
  • Hang Seng

    16,536.85
    -253.95 (-1.51%)
     
  • NIKKEI 225

    39,208.03
    0.00 (0.00%)
     

This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie

This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie

AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). Let's examine the data from the clinical trial and the U.S. UC market to resolve this question. Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes damage to the gastrointestinal (GI) tract.